About Atreus Pharmaceuticals
Atreus Pharmaceuticals is a Healthcare company based in Ottawa (Canada) founded in 2007, and was acquired by Advanced Accelerator Applications in January 2015. In vivo imaging diagnostics for autoimmune diseases are developed. Atreus Pharmaceuticals has raised $6 million across 1 funding round from investors including Advanced Accelerator Applications. The company was acqui-hired. Its focus areas include Life Sciences, Immunology, In Vitro Diagnostic Tests and Diversified.
Company details
Atreus Pharmaceuticals was focussed on developing in-vivo radiopharmaceutical products for Nuclear Medicine (SPECT) imaging and for PET imaging. Its product line was based on the Annexin V human protein, which binds to phosphatidylserine, a molecule that only shows up on the surface of dead or dying cells. Its lead diagnostic product Annexin V-128 was in phase 12 trials for rheumatoid arthritis and ankylosing spondylitis. It also claims that the compound when used with the medical isotope Technetium-99, has the ability to be used to evaluate the response to treatment for lymphoma and lung cancer. In January 2015, Advanced Accelerator Applications (AAA) fully acquired Atreus.
- Headquarters Ottawa, Canada
- Stage Acquired
- SectorsHealthcare
- Website atreuspharma.com
- Acquired by Advanced Accelerator Applications (Jan 2015)
- Total Equity Funding$6M (USD)
in 1 rounds
- Latest Funding Round$6M (USD), Series A
Mar 2010
- Investors
- Acquired byAdvanced Accelerator Applications
(Jan 2015)
Funding Insights of Atreus Pharmaceuticals
Atreus Pharmaceuticals has successfully raised a total of $6M through 1 strategic funding round. The most recent funding activity was a Series A round of $6 million completed in March 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6M
- Total Rounds 1
- Last Round Series A — $6M
- First Round $6M
(Mar 2010)
- Investors Count 1
All 1 funding rounds of Atreus Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2010 | $6M | Series A | – | – |
1 investors in total: 1 institutional.
Investors in Atreus Pharmaceuticals
Atreus Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Advanced Accelerator Applications.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | adacap.com | Saint Genis Pouilly, France |
Investor details for Atreus Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Atreus Pharmaceuticals
3 dated milestones of Atreus Pharmaceuticals across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Atreus Pharmaceuticals is founded.
- Funding First funding round of $6.0M.
- Exit Acquired by Advanced Accelerator Applications.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Atreus Pharmaceuticals
Atreus Pharmaceuticals was founded in 2007 and raised its 1st funding round 3 years after it was founded.
Atreus Pharmaceuticals is headquartered in Ottawa, Canada. It is registered at Ottawa, Ontario, Canada.
Atreus Pharmaceuticals is a funded company, having raised a total of $6M across 1 funding round to date. The company's 1st funding round was a Series A of $6M, raised on Mar 2010.
Atreus Pharmaceuticals was focussed on developing in-vivo radiopharmaceutical products for Nuclear Medicine (SPECT) imaging and for PET imaging. Its product line was based on the Annexin V human protein, which binds to phosphatidylserine, a molecule that only shows up on the surface of dead or dying cells. Its lead diagnostic product Annexin V-128 was in phase 12 trials for rheumatoid arthritis and ankylosing spondylitis. It also claims that the compound when used with the medical isotope Technetium-99, has the ability to be used to evaluate the response to treatment for lymphoma and lung cancer. In January 2015, Advanced Accelerator Applications (AAA) fully acquired Atreus.
Atreus Pharmaceuticals has 1 investor. Key investors include Advanced Accelerator Applications.
Yes. Atreus Pharmaceuticals was acquired by Advanced Accelerator Applications in January 2015.